Aardvark Medical v. Guangdong XINRUNTAO: Dismissed Without Prejudice After 485 Days
Aardvark Medical Inc. sued Guangdong XINRUNTAO Technology Co., Ltd. in the Eastern District of Texas asserting five patents covering nasal irrigation and aspiration devices, including the Gailyus Nasal Irrigation System. After 485 days, the plaintiff voluntarily dismissed all claims without prejudice under Rule 41, with each party bearing its own costs.
Five Nasal Irrigation Patents, One Voluntary Exit Before Any Defense Filed
On February 18, 2025, Aardvark Medical Inc. filed an infringement action in the U.S. District Court for the Eastern District of Texas (Case No. 2:25-cv-00217), before Judge Rodney Gilstrap, asserting five U.S. patents — US11883009B2, US11889995B2, US11883010B2, US9750856B2, and US11318234B2 — against Guangdong XINRUNTAO Technology Co., Ltd. The accused products are nasal irrigation and aspiration devices, including the Gailyus Nasal Irrigation System.
The recorded basis of termination is 'Dismissed without Prejudice.' The docket order states that Aardvark Medical filed a Notice of Voluntary Dismissal Without Prejudice pursuant to Rule 41(a)(1)(A)(i), which the court accepted and acknowledged, directing the Clerk to close the case. The order further states that each party is to bear its own costs, expenses, and attorneys' fees, and all pending relief requests not explicitly granted are denied as moot.
Notably, the dismissal was filed before Guangdong XINRUNTAO had answered the complaint or moved for summary judgment, meaning no substantive defense was ever entered on the record. The specific reasons driving Aardvark Medical's decision to withdraw are not disclosed in the available public record. Because the dismissal was entered without prejudice, Aardvark Medical retains the ability to refile claims under these patents against this defendant or others, making the disposition a pause rather than a final resolution.
See Complete Case & Patent Analysis →Filing to Dismissed without Prejudice in 485 days
485 days from filing to closure — resolved before any answer or summary judgment motion
US11883009B2 and four further patents — nasal irrigation and aspiration devices
Any company designing, manufacturing, importing, or distributing nasal irrigation or aspiration devices — including OEM suppliers and private-label distributors — should assess freedom-to-operate against the five Aardvark Medical patents asserted in this action. The dismissal without prejudice means these patents are unresolved enforcement risks. The accused Gailyus Nasal Irrigation System product category is broad enough to implicate a wide range of competitive devices.
Official order — verbatim text
The court's order accepted Aardvark Medical's Rule 41(a)(1)(A)(i) notice, confirming all claims are dismissed without prejudice before any responsive pleading was filed. No merits determination was made. The own-costs directive is standard for pre-answer voluntary dismissals and does not reflect any finding on the strength of the asserted patents or the accused Gailyus Nasal Irrigation System products.
Dismissed without prejudice: what the voluntary withdrawal means for both parties
Rule 41(a)(1)(A)(i): dismissal as of right before any answer
Under Rule 41(a)(1)(A)(i), a plaintiff may voluntarily dismiss without prejudice before the defendant serves an answer or moves for summary judgment — no court approval is required, though the court here formally accepted and acknowledged the notice. This is a unilateral procedural exit, not a negotiated settlement or court ruling on the merits.
No merits adjudicationWithout prejudice: Aardvark Medical can refile these claims
A dismissal without prejudice does not extinguish the underlying patent rights or bar future infringement suits on the same patents. Aardvark Medical retains the option to refile against Guangdong XINRUNTAO or other parties. Whether and when it may do so depends on strategic and commercial considerations not disclosed in the available record.
Refiling possibleXINRUNTAO exits without admissions — but exposure remains open
Guangdong XINRUNTAO Technology Co., Ltd. never filed an answer, so no admissions, invalidity arguments, or non-infringement positions were placed on record. The dismissal without prejudice means the threat of litigation under these five patents has not been permanently resolved. XINRUNTAO bears no liability from this action but faces continued exposure.
No liability — exposure persistsFive live patents still enforceable in the nasal irrigation device market
With no invalidity ruling and no covenant not to sue on record, all five Aardvark Medical patents remain fully enforceable. Competitors and distributors of nasal irrigation and aspiration devices — particularly those sourcing from Chinese manufacturers — should note that these patents were asserted and remain active. The own-costs order leaves no financial deterrent on either side to future action.
Patents remain enforceableFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Aardvark Medical Inc. | Company | /Search in Eureka ↗ |
| Defendant | Guangdong XINRUNTAO Technology Co., Ltd. | Company | /Search in Eureka ↗ |
| Plaintiff counsel | Alfred Ross Fabricant | Attorney | Counsel for Aardvark Medical Inc.Search in Eureka ↗ |
| Plaintiff counsel | Evan Langdon | Attorney | Counsel for Aardvark Medical Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jennifer Leigh Truelove | Attorney | Counsel for Aardvark Medical Inc.Search in Eureka ↗ |
| Plaintiff counsel | Joseph Michael Mercadante | Attorney | Counsel for Aardvark Medical Inc.Search in Eureka ↗ |
| Plaintiff law firm | Fabricant LLP | Law Firm | Representing Aardvark Medical Inc.Search in Eureka ↗ |
| Plaintiff law firm | Fabricant, Rubino & Lambrianakos LLP | Law Firm | Representing Aardvark Medical Inc.Search in Eureka ↗ |
| Plaintiff law firm | McKool Smith PC (Marshall) | Law Firm | Representing Aardvark Medical Inc.Search in Eureka ↗ |
| Presiding judge | Judge Rodney Gilstrap | Judge | Texas Eastern District CourtSearch in Eureka ↗ |
R&D signals in the nasal irrigation and aspiration device space
Forward-looking patent and innovation intelligence derived from the Aardvark Medical portfolio and the broader nasal care device technology landscape.
Aardvark Medical's continuation strategy signals active portfolio expansion
Three of the five asserted patents share 2023 application numbers in the US18/324xxx series, consistent with a deliberate continuation filing strategy. This suggests Aardvark Medical may be prosecuting additional claims in this family. R&D teams and competitors should monitor pending continuations from these application numbers for emerging claim scope that could broaden enforcement reach.
Active continuation familiesNasal irrigation device patent filings are accelerating — mapping the competitive field
The nasal irrigation and aspiration device category has seen growing patent activity from both medical device incumbents and consumer health OEMs. Filing trends around irrigation system design, aspiration mechanisms, and fluid delivery control are worth tracking for R&D teams developing next-generation nasal care products, particularly where Chinese manufacturers are active.
Growing filing activityGuangdong XINRUNTAO's patent posture in nasal care devices
As the named defendant, Guangdong XINRUNTAO Technology Co., Ltd. filed no answer and placed no invalidity or non-infringement arguments on record. Understanding XINRUNTAO's own patent filings and R&D activity in the nasal irrigation segment can help assess their defensive IP position and inform competitive intelligence for others in the supply chain.
Defensive posture unclearDesign-around and adjacent white space near the Aardvark Medical claims
With five patents covering nasal irrigation and aspiration across multiple continuation generations, identifying unclaimed design space requires detailed claim mapping. Adjacent technical approaches — such as alternative fluid delivery mechanisms, aspiration control methods, or novel materials — may represent white-space opportunities for competitors seeking to enter this market without infringing the Aardvark Medical portfolio.
Design-around potentialSimilar nasal irrigation and medical device patent cases in E.D. Texas
Browse comparable patent infringement actions involving nasal care and medical device technology filed in the Eastern District of Texas before Judge Gilstrap.
What this case signals for the nasal irrigation device IP landscape
A five-patent assertion dropped before any defense was filed raises questions about enforcement strategy and competitive dynamics in the nasal care device market.
Early voluntary dismissal often signals a strategic pivot, not a defeat
When a plaintiff dismisses before a defendant answers, it typically suggests a change in enforcement strategy, ongoing licensing discussions, or identification of a stronger target or venue. The public record is silent on the reason here, but all five patents remain live assets for Aardvark Medical.
Nasal irrigation device IP is an active enforcement zone — monitor closely
The assertion of five patents against a Chinese OEM in the Eastern District of Texas suggests Aardvark Medical is actively defending its position in the nasal care device market. Companies sourcing or distributing nasal irrigation products should assess their FTO exposure against these specific patent numbers.
Aardvark v Guangdong — key questions answered
Aardvark Medical asserted five U.S. patents: US11883009B2, US11889995B2, US11883010B2, US9750856B2, and US11318234B2. All five cover nasal irrigation and aspiration device technology. The accused products include the Gailyus Nasal Irrigation System.
Aardvark Medical filed a Notice of Voluntary Dismissal Without Prejudice under Rule 41(a)(1)(A)(i) before Guangdong XINRUNTAO had answered the complaint or moved for summary judgment. The specific reasons for the dismissal are not disclosed in the available public record.
Yes. A dismissal without prejudice does not extinguish Aardvark Medical's patent rights or bar future litigation on the same patents. All five asserted patents remain enforceable. A subsequent filing on the same claims against the same defendant would be subject to the two-dismissal rule under Rule 41(a)(1)(B), which would operate as an adjudication on the merits.
The court ordered each party to bear its own costs, expenses, and attorneys' fees. This is standard for a pre-answer voluntary dismissal under Rule 41(a)(1)(A)(i) and does not reflect any finding on the merits, the validity of the patents, or the strength of the infringement claims.
Aardvark Medical was represented by Alfred Ross Fabricant, Evan Langdon, Jennifer Leigh Truelove, and Joseph Michael Mercadante. The plaintiff law firms on record are Fabricant LLP, Fabricant, Rubino & Lambrianakos LLP, and McKool Smith PC (Marshall office). No defendant counsel is listed in the available record.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.